Retatrutide vs tirzepatide: no trial has compared them in people, and what that means for every number you have seen

No trial has compared them. Retatrutide and tirzepatide have never been given to the same group of people in the same study. Every number that puts them side by side comes from separate trials or from statistical modelling across trials.

Why the usual comparison fails. The figure quoted for retatrutide, 24.2%, is from a phase 2 trial in 338 adults over 48 weeks. The figure quoted for tirzepatide, 20.9%, is from a phase 3 trial in 2,539 adults over 72 weeks. Different size, different stage, different length, different people.

What can legitimately be said. A 2026 network meta-analysis of 58 trials estimated 22.1% for retatrutide and 19.3% for tirzepatide against placebo, and said in the same breath that the confidence intervals overlap and head-to-head evidence is limited.

The status difference is the bigger one. Tirzepatide is an approved medicine with a label, a manufacturer and a supply chain. Retatrutide is investigational, in phase 3, approved nowhere, so anything sold under the name today is unregulated and its contents are unverified.

Where the evidence is thinnest. Switching between them, which nobody has studied; long-term safety of the glucagon arm; and body composition, which the two trials did not measure the same way.

A head-to-head trial randomises the same population to both drugs and follows them for the same length of time. For these two, that trial does not exist. It has not been completed, and no published result reports one.

This is not an oversight nobody noticed. A 2023 commentary in the investigational-drugs literature made the point directly while retatrutide's phase 2 results were still fresh: the comparison it needed was with tirzepatide, and the comparison it had was not meaningful. Three years later, that is still where things stand.

Both drugs come from the same company, which is one reason a direct comparison is unlikely to be anybody's priority. A trial showing the newer drug beats the older one by a wide margin would be as commercially awkward as one showing it does not.

What exists instead is indirect evidence: statistical comparison of each drug against placebo across separate trials, adjusted for what the trials had in common. That is a legitimate method with a known weakness, which is that it inherits every difference between the trials it pools.

Read the length row against the weight row. Retatrutide's curve was still falling when its trial stopped: the 12 mg group went from 17.5% at 24 weeks to 24.2% at 48. Tirzepatide's trial ran 24 weeks longer, by which point weight curves in this drug class have generally flattened. Whatever the true difference between these drugs is, the published figures do not measure it.

The meta-analysis is the one worth reading carefully, because it is the only estimate built for this purpose. Its own conclusion is hedged: differences in tolerability, limited head-to-head evidence and residual uncertainty should be considered when interpreting comparative treatment effects. That sentence is doing more work than the ranking it accompanies.

The same analysis places CagriSema, the cagrilintide and semaglutide combination, at 17.3%, and conventional GLP-1 drugs below that. The ordering is consistent across analyses even where the individual gaps are not statistically resolved.

Tirzepatide activates two receptors: GLP-1, which slows gastric emptying and signals fullness, and GIP, which appears to improve how well the GLP-1 arm is tolerated as much as it adds effect of its own. Retatrutide activates those two and a third, the glucagon receptor.

Adding glucagon is counterintuitive, since glucagon raises blood sugar. The rationale is energy expenditure: glucagon receptor activation increases metabolic rate and mobilises fat from the liver, and pairing it with GLP-1 is meant to offset the glucose effect. In the phase 2 trial, blood sugar control improved rather than worsened, which is the evidence that the pairing works at these doses.

The glucagon arm is also where the long-term uncertainty sits. It is the least characterised of the three in chronic human use, it is the part most associated with dose-dependent heart-rate increases, and it is the reason the phase 3 programme matters more here than it would for a fourth GLP-1 drug.

There is no dose equivalence between them and no published conversion. The two act on different combinations of receptors, so milligrams of one are not milligrams of the other in any meaningful sense, and the retatrutide doses in the table are the doses a dose-finding trial tested rather than a dose anyone settled on.

Tirzepatide's label figures are quoted here from the approved prescribing information, which is not yet in this record's ledger; they are marked editorial for that reason.

Both are dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, worst during escalation and easing afterwards. Both trials report them as the most common adverse events. That much is common ground.

Comparing rates is where it breaks down. The trials asked over different lengths of time, in different populations, with different escalation schedules, and adverse-event reporting is sensitive to all three. A drug studied for 72 weeks accumulates more reported events than one studied for 48 simply by running longer.

The pooled analyses are more informative than either trial here. A 2026 systematic review of dual and triple agonists found the class carried a higher risk of any adverse event than placebo, roughly twice the risk of withdrawal for adverse events, and three times the rate of hypoglycaemic episodes, with no significant difference in serious adverse events. The 2026 network meta-analysis added that discontinuation appeared higher with retatrutide specifically, on low-certainty evidence.

The one effect that belongs to retatrutide's third receptor is heart rate. Increases were dose-dependent in the phase 2 trial and largest in the first half. What that means over years is what phase 3 exists to find out.

Nothing. No trial has enrolled people already taking tirzepatide, no published study describes stopping one and starting the other, and no dose conversion has been established. The searches for this are substantial and the literature behind them is empty.

What can be said generally is that both are once-weekly injections with multi-week escalation schedules, and that tolerance to gastrointestinal effects is built during escalation rather than carried between drugs. Beyond that, anything specific about switching is somebody's inference, and this page does not make it.

Tirzepatide was approved in 2022 and is a prescription medicine with a label, a manufacturer and a regulated supply chain, sold under brand names for diabetes and for weight management.

Retatrutide is investigational. Its phase 3 programme is running and no regulator has approved it anywhere. There is no legal route to obtain it outside a trial.

That gap is the origin of the grey market. Material sold online as retatrutide is not made by the company running the trials, is not covered by any approval, and has not been shown to contain what the label says. The doses in this page's table were given under trial monitoring with known material, which is what makes them meaningful; they carry no information about an unverified vial.

Each compound's own record carries its full evidence: retatrutide and tirzepatide.

Supported: both produce weight loss far beyond older GLP-1 drugs; retatrutide's phase 2 numbers are higher than tirzepatide's phase 3 numbers; indirect analyses rank retatrutide first with overlapping intervals; the class shares its side-effect profile and its escalation problem.

Not supported: that retatrutide is more effective than tirzepatide by a specific margin; that either is better tolerated; that one preserves more lean mass; that a given dose of one corresponds to a dose of the other; that results in a trial transfer to unverified material bought online.

The honest summary is that one of these is a medicine and the other is a candidate with a striking phase 2 result. Those are different kinds of thing, and the comparison people want will exist only when a trial gives both to the same people, or phase 3 results let the indirect analyses be redone with matched populations.

1. Treating 24.2% and 20.9% as comparable. Forty-eight weeks against seventy-two, 338 people against 2,539, phase 2 against phase 3.
2. Reading a meta-analysis ranking as a measured difference. Overlapping confidence intervals mean the ordering is probable, not established.
3. Assuming head-to-head data exists somewhere. The eight studies in this record that name both are reviews, meta-analyses and animal work. The only one that gave both to the same subjects used mice.
4. Converting doses between them. There is no equivalence, and the retatrutide figures come from a dose-finding trial.
5. Carrying trial results across to grey-market material. The trials used the manufacturer's drug under monitoring.
6. Expecting the 24-week figure to be the final answer. Retatrutide's curve was still falling at 48 weeks; phase 3 runs longer and may land anywhere.